RHY 0.00% 10.0¢ rhythm biosciences limited

Ann: CE Mark Granted for ColoSTAT, page-40

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,456 Posts.
    lightbulb Created with Sketch. 2799
    "You do realise that the $12b or total market opportunity refers to the value of tests." Yes I do, and I also see that the most recent analysis shows licensing revenue in FY24 as about $17m which is about 0.1% of the total market opportunity in Europe. Call me reckless but to me that stinks of an analyst playing it cautious.

    If they are out there selling kits into the European market then I think a reasonable share of the market would be say 10% which is $1.2b less expenses. If they go pure licensing then I reckon a 1% clip would be reasonable which would give them net $120m. Just to be conservative give them only a quarter of the market and even then the licensing charge should be about twice what the analyst used in her model.

    And yes, ColoSTAT is a threat to Sonic's current business as it can wipe out the FIT market which Sonic plays in.
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
(20min delay)
Last
10.0¢
Change
0.000(0.00%)
Mkt cap ! $24.85M
Open High Low Value Volume
10.0¢ 10.0¢ 9.9¢ $10.30K 103.2K

Buyers (Bids)

No. Vol. Price($)
1 95000 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 17500 1
View Market Depth
Last trade - 13.28pm 31/10/2024 (20 minute delay) ?
RHY (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.